The complexity of Combination Products and their regulations

Combination Products are a major growth area for pharmaceutical and medical device companies: Combination Products allow the creation of platform delivery systems, the combination of technologies, and novel ways of treatment. Most pharma companies already have Combination Products in their portfolio and medical device companies are increasingly involved in their design and development.

Combination Products

By definition, Combination Products consist of drug, device or biologics constituent parts. In general, each constituent part is required to meet its own set of regulations, even if the overall product is governed by a different regulation. As a result, pharmaceutical companies have to deal with areas that they are less familiar with and that do not fit into their typical organizational structures. For example, for a pre-filled syringe a pharmaceutical company may have to consider compatibility issues, or has to carry out human factor studies or device risk assessments that consider use error. Similarly, device companies will have to familiarize themselves with medicinal product or biologics regulations that they are less familiar with.

How can companies effectively leverage existing processes and structures in order to stay compliant and operationally effective for Combination Products in their portfolio?

Companies should not need to re-invent the wheel in order to integrate Combination Products in their portfolio. However, a full review of governance, existing processes and technologies is required to stay compliant; whilst many drug, device and biologics processes are similar, there are differences in approach that need to be addressed.

Navitas assesses the suitability of existing drug or device processes

Navitas offers a full review of suitability and capabilities of existing processes, technologies and governance models for Combination Products and Medical Devices. We typically start with a gap analysis that helps clients to proactively identify gaps and shortcomings in current regulatory, quality or safety processes and supports inspection readiness and compliance. Navitas aims to not only ensure full compliance with regulations but also to identify and implement efficiency gains and performance improvement opportunities while revising the process and governance models.

Navitas typically carries out a high-level review in a first phase of a medical device or Combination Product process project. A second phase provides detailed technical, process and organizational solutions and draws in experts from within the client and Navitas with relevant device or pharmaceutical expertise for, for example, the US or European market. Navitas also guides the client into the third phase which usually represents the implementation and ensures that tasks are executed and improvements are realized as planned. We pride ourselves in achieving buy-in throughout all project phases and aim to create implementation plans and solutions that provides quick wins and are realistic as well as efficient.

  • All
  • AMS
  • BI
  • Brochure
  • CaseStudy
  • Clinical
  • CMS
  • MedicalDevices
  • On DemandWebinar
  • Quality
  • Regulatory
  • Safety
  • Technology
  • Whitepaper

Latest News


ICH Reflection on “GCP Renovation”: Modernization of ICH E8 and...

Navitas welcomes the opportunity to provide comments on this Reflection Paper... Navitas welcomes the opportunity...


Navitas Life Sciences Augments Global Executive Management Team

Navitas Life Sciences announced the appointment of Dr. Krishnan Rajagopalan as Chief Growth Officer....


Navitas Networks announce Forum dates for Spring, 2017

The Navitas Networks are pleased to confirm the dates for our upcoming Spring forums... ...


Navitas Launches Labeling Assessment Express

Regulators are changing the way they look at labeling. The emphasis is on ensuring...


BioVectra chooses pharmaREADY for eCTD Solution

BioVectra has chosen pharmaREADY for its eCTD requirements. BioVectra, located in Canada, manufactures...


Navitas at DIA's 10th Annual Forum for Qualified Persons...

Navitas Principal Jeffrey Ho will present "Efficient content management for the compilation and...


News 2016

[row id="1" class="ROW_CLASS"] [col class="span12"] 02 Nov 2016 AbbVie and Navitas Present Case Study on the Evolution...


Navitas releases paper on CDISC, the standards and why the...

The FDA (and eventually, regulatory agencies from around the world) will require clinical data...


AbbVie and Navitas Present Case Study on the Evolution and...

At 10:30a.m. (East Coast Time) on September 22nd, Navitas and AbbVie will...


Navitas Networks announce Forum dates for Autumn, 2016

The Navitas Networks are pleased to confirm the dates for our upcoming Autumn forums....


Navitas Celebrates 100th pharmaREADY customer

pharmaREADY is Navitas’ intuitive and easy to use, fully integrated, regulatory compliant, web-based suite...


Navitas' PVTech Summit Defines Future Success

Navitas’ PVTech Summit was held on June 15th at the Hudson Hotel in New...


Navitas Welcomes Tara Baer to Navitas

Navitas is pleased to welcome Tara Baer, who joins Navitas' Regulatory Practice. With over...


Navitas Speaks at Sparta Connection in Orlando

David Gwyn, Navitas' Technology Practice lead, will unveil idmpREADY at the Sparta Connection conference...


Navitas Earns Speaking Sessions at DIA’s 52nd Annual Meeting

In two different sessions, Subject Matter Experts from Navitas will address new challenges facing...


Navitas is pleased to announce the introduction of our networks...

Navitas' inaugural pvindia meeting took place in Mumbai on Thursday 03 March, 2016. ...


Navitas Announces the Inaugural pvindia Forum

Navitas will soon be adding to our portfolio of industry leading networks with the...


Navitas Relaunches is Navitas' next generation website for its fully integrated, regulatory compliant document management,...


Steve Arlington, Navitas Advisor, Spoke on the Challenges, Opportunities and...

Steve Arlington, Navitas Advisor, Spoke on the Challenges, Opportunities and Future of the Pharmaceutical...


The changing trends in drivers of life sciences R D...

Outsourcing is not new in the life sciences sector. Clinical research outsourcing, contract sales...